~39.0, driven by strong volumes in high-realisation segments such as Pharma and F&F. Consequently, the EBITDA margin expanded by 110 bps YoY. Looking ahead, we expect higher volumes and revenue driven by pent-up deF&F segments. We project a topline CAGR of 15.4% over FY25AFY27E, with earnings expected...